115 related articles for article (PubMed ID: 29474871)
1. Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum.
Leino S; Koski SK; Rannanpää S; Salminen O
Neurosci Lett; 2018 Apr; 672():40-45. PubMed ID: 29474871
[TBL] [Abstract][Full Text] [Related]
2. Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
Leino S; Kohtala S; Rantamäki T; Koski SK; Rannanpää S; Salminen O
BMC Neurosci; 2018 Nov; 19(1):77. PubMed ID: 30497382
[TBL] [Abstract][Full Text] [Related]
3. Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
Quik M; Mallela A; Chin M; McIntosh JM; Perez XA; Bordia T
Neurobiol Dis; 2013 Feb; 50():30-41. PubMed ID: 23009753
[TBL] [Abstract][Full Text] [Related]
4. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Huang LZ; Campos C; Ly J; Ivy Carroll F; Quik M
Neuropharmacology; 2011 May; 60(6):861-8. PubMed ID: 21232546
[TBL] [Abstract][Full Text] [Related]
6. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
7. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of bupropion on nicotinic receptor-evoked [(3)H]dopamine release from rat striatal synaptosomes and slices.
Sidhpura N; Redfern P; Wonnacott S
Eur J Pharmacol; 2007 Jul; 567(1-2):102-9. PubMed ID: 17477919
[TBL] [Abstract][Full Text] [Related]
9. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
[TBL] [Abstract][Full Text] [Related]
10. Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
Speck AE; Schamne MG; S Aguiar A; Cunha RA; Prediger RD
Mol Neurobiol; 2019 Apr; 56(4):2944-2951. PubMed ID: 30073506
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
[TBL] [Abstract][Full Text] [Related]
12. Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.
Bordia T; Perez XA; Heiss J; Zhang D; Quik M
Neurobiol Dis; 2016 Jul; 91():47-58. PubMed ID: 26921469
[TBL] [Abstract][Full Text] [Related]
13. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
14. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
Cote SR; Chitravanshi VC; Bleickardt C; Sapru HN; Kuzhikandathil EV
Behav Brain Res; 2014 Apr; 263():46-50. PubMed ID: 24462727
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Mallela A; Sohn D; Carroll FI; Bencherif M; Letchworth S; Quik M
J Pharmacol Exp Ther; 2013 Oct; 347(1):225-34. PubMed ID: 23902940
[TBL] [Abstract][Full Text] [Related]
17. Selective down-regulation of [(125)I]Y0-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine.
Mugnaini M; Garzotti M; Sartori I; Pilla M; Repeto P; Heidbreder CA; Tessari M
Neuroscience; 2006; 137(2):565-72. PubMed ID: 16289885
[TBL] [Abstract][Full Text] [Related]
18. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum.
Wonnacott S; Kaiser S; Mogg A; Soliakov L; Jones IW
Eur J Pharmacol; 2000 Mar; 393(1-3):51-8. PubMed ID: 10770997
[TBL] [Abstract][Full Text] [Related]
19. Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum.
Grady S; Marks MJ; Wonnacott S; Collins AC
J Neurochem; 1992 Sep; 59(3):848-56. PubMed ID: 1494911
[TBL] [Abstract][Full Text] [Related]
20. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
